Eli Lilly (LLY) and Amgen (AMGN) filed a complaint Friday against the US Department of Health and Human Services, alleging that the agency unlawfully certified and recertified clinics that treat sexually transmitted diseases to participate in a federal drug discount program.
The plaintiffs said in the lawsuit that the court "should set aside the agency's unlawful certifications and recertifications of these ineligible entities and enjoin the agency from certifying or recertifying these entities in the future."
The Department of Health and Human Services did not immediately reply to a request for comment from MT Newswires.
Price: 791.19, Change: +23.43, Percent Change: +3.05
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。